Pharmaceutical Technology-03-02-2012

Solubility : Using Nanotechnology to Tackle Key Challenges in Bioavailability

The standardization of upstream and downstream bioprocessing is growing, but several kinks need to be ironed out.

Nanosupensions are among the ways formulation scientists seek to address the problem of solubility.

In a world where product recalls can mean the end of a company, all batches must be perfect.

Regulatory bodies, standard-setting organizations, and industry seek to tackle the problem of counterfeit drugs and securing the flow of pharma ingredients.

The divide between innovation and conflict of interest in medical research is not so clear.

Genotoxic impurities and how to identify them and control for them have been a concern for several years in the pharmaceutical manufacturing industry. Pharmaceutical Technology spoke with Bo Shen, PhD, principal scientist at Amgen and chair of the AAPS Pharmaceutical Trace Impurities Focus Group, to gain insight on key challenges.

Brazil's generic-drug market is growing steadily.

US Pharmacopeia documents best supply-chain practices and seeks broad input on proposal.

In Part II of a three-part article, the authors examine impurities from chiral molecules, polymorphic contaminants, and genotoxic impurities.

Wirelessly controlled microchips may offer an alternative to injection-based drug delivery

SOCMA's Bulk Pharmaceuticals Task Force outlines key goals and challenges for user-fee legislation.

Has the long-awaited guidance answered all of the industry's questions?

Social media use raises questions about applying old standards to new information technology.

FDA's treatment of whistleblowers lacks internal consistency.

New product reviews for March 2012.

The evolving bio/pharmaceutical business model poses risk for CMOs.

A Q&A with Chris Meissner, president of Meissner Filtration Products, on recent industry trends.